Showing 581 - 600 results of 42,684 for search '(( 50 ((ppm decrease) OR (a decrease)) ) OR ( 5 ((ng decrease) OR (we decrease)) ))', query time: 0.82s Refine Results
  1. 581
  2. 582
  3. 583

    DataSheet2_WNT5A Interacts With FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells.docx by Tianqi Li (1335987)

    Published 2022
    “…Among the various receptors that have been reported to interact with WNT5A, we found FZD5 abundantly expressed by eMSC when compared to unfractionated stromal cells. …”
  4. 584

    DataSheet1_WNT5A Interacts With FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells.docx by Tianqi Li (1335987)

    Published 2022
    “…Among the various receptors that have been reported to interact with WNT5A, we found FZD5 abundantly expressed by eMSC when compared to unfractionated stromal cells. …”
  5. 585
  6. 586
  7. 587
  8. 588
  9. 589
  10. 590
  11. 591
  12. 592
  13. 593

    Hsa_circ_0017639 regulates cisplatin resistance and tumor growth via acting as a miR-1296-5p molecular sponge and modulating sine oculis homeobox 1 expression in non-small cell lun... by Feiyun Chang (12243382)

    Published 2022
    “…The regulation mechanism of circ_0017639 was demonstrated by a dual-luciferase reporter assay. We observed higher levels of circ_0017639 in DDP-resistant NSCLC samples and cells. …”
  14. 594
  15. 595
  16. 596
  17. 597
  18. 598

    DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  19. 599
  20. 600